Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination injectable product containing the corticosteroid betamethasone (typically as both sodium phosphate and acetate esters) and a local anesthetic (commonly lidocaine or bupivacaine). The corticosteroid component acts by suppressing inflammation through inhibition of multiple inflammatory cytokines and immune mediators. The local anesthetic component stabilizes neuronal membranes by inhibiting ionic fluxes required for initiation and conduction of nerve impulses, resulting in localized numbness. This combination is used for intra-articular, intralesional, perineural, or infiltration injections to provide both rapid pain relief from the anesthetic and prolonged anti-inflammatory effects from the steroid. It is indicated for conditions such as arthritis flares, bursitis, tenosynovitis, acute gouty arthritis exacerbations, soft tissue inflammation/injury management, and other musculoskeletal disorders[2][4][5]. Caution is advised due to potential chondrotoxicity when injected into joints[1], as well as possible precipitation/crystal formation depending on which specific agents are mixed[3][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on betamethasone + local anesthetic.